---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-221288"
form_type: "8-K"
ticker: "IKT"
cik: "0001750149"
company_name: "Inhibikase Therapeutics, Inc."
filed_at: "2022-08-15T23:59:59+00:00"
generated_at: "2026-06-23T23:58:01.635381+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "low"
source: SEC EDGAR
---

# Inhibikase posts corporate presentation; no specific financial or clinical data in filing

## Summary
- Presentation made available on company website on Aug 15, 2022, for investor presentations.
- Filing includes only cover page and disclaimer; full slide deck not reproduced in the 8-K.
- Presentation is dated 3Q 2022 and focuses on neurodegenerative disease and cancer therapeutics.
- No new financial results, guidance, or clinical milestones were disclosed in this filing.

## SEC filing metadata
- accession: 0001193125-22-221288
- form_type: 8-K
- ticker: IKT
- cik: 0001750149
- company_name: Inhibikase Therapeutics, Inc.
- filed_at: 2022-08-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750149/000119312522221288/0001193125-22-221288-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750149/000119312522221288/d395011d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-221288
- JSON: https://secwatch.observer/filing/0001193125-22-221288.json
- Plain text: https://secwatch.observer/filing/0001193125-22-221288.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.